^
    Back
    Association details:
    Biomarker:Chr del(17p)
    Cancer:Chronic Lymphocytic Leukemia
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic lymphocytic leukemia/Small lymphocytic lymphoma: Suggested treatment regimens...CLL/SLL with del(17p)/TP53 mutation…relapsed/refractory therapy…other recommended regimens…lenalidomide ± rituximab
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia

    Published date:
    12/01/2020
    Excerpt:
    Phase II study randomized 49 patients with genetically high-risk CLL or small lymphocytic lymphoma [SLL; defined as unmutated Ig heavy chain variable region, deletion(17p) or (11q), and/or complex abnormal karyotype], to receive lenalidomide...PFS at 1, 2, and 3 years was 85% (95% CI, 72-93), 79% (95% CI, 64-88), and 72% (95% CI, 57-83), respectively.
    DOI:
    10.1158/1078-0432.CCR-20-1280